Adma Biologics Inc (ADMA) valuation
Adma Biologics P/E ratio history
Adma Biologics trades at 16.3 times its earnings over the last twelve months and 13.1 times the earnings analysts expect over the next twelve.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 31, 2025 | $18.24 | $0.60 | 30.4 | 22.6 |
| Dec 31, 2024 | $17.15 | $0.81 | 21.2 | 25.4 |
| Dec 31, 2023 | $4.52 | -$0.13 | n/m | 40.1 |
| Dec 31, 2022 | $3.88 | -$0.33 | n/m | — |
| Dec 31, 2021 | $1.41 | -$0.51 | n/m | — |
| Dec 31, 2020 | $1.95 | -$0.88 | n/m | — |
| Dec 31, 2019 | $4.00 | -$0.89 | n/m | — |
| Dec 31, 2018 | $2.39 | -$1.46 | n/m | — |
| Dec 31, 2017 | $3.21 | -$1.89 | n/m | — |
| Dec 31, 2016 | $5.12 | -$1.62 | n/m | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Adma Biologics valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| Adma BiologicsADMA | $2.65B | 16.3 | 13.1 | 5.2 |
| AxogenAXGN | $2.65B | — | 73.6 | 9.9 |
| Mbx BiosciencesMBX | $2.66B | — | — | — |
| Enliven TherapeuticsELVN | $2.69B | — | — | — |
| Privia Health GroupPRVA | $2.71B | 97.6 | 22.0 | 1.2 |
| Guardian Pharmacy Services Inc ClaGRDN | $2.58B | 39.5 | 29.8 | 1.8 |
| NeogenNEOG | $2.58B | — | 32.6 | 2.9 |
| Viridian Therapeutics OrsVRDN | $2.54B | — | — | 35.8 |
| Dyne TherapeuticsDYN | $2.76B | — | — | — |
| Peer median | 68.6 | 31.2 | 2.9 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: ADMA financials · ADMA returns
No forecast, no recommendation. This page describes Adma Biologics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.